Pivotal ALPHA Phase III trial results will show benefit of danicopan, Alexion’s first-in- class Factor D inhibitor, in improving clinically significant extravascular haemolysis while allowing patients with PNH to remain on standard of care treatment Calquence data will reinforce role as a preferred treatment option for chronic lymphocytic leukaemia and mantle cell lymphoma Interim clinical data will show promise of …